Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.

Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ.

Value Health. 2005 May-Jun;8(3):191-200.

2.
3.

Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.

Avritscher EB, Cantor SB, Shih YC, Escalante CP, Rivera E, Elting LS.

Support Care Cancer. 2004 Jul;12(7):531-6. Epub 2004 Feb 21.

PMID:
14986076
4.

Hospital-based costs associated with venous thromboembolism treatment regimens.

Merli G, Ferrufino C, Lin J, Hussein M, Battleman D.

J Thromb Haemost. 2008 Jul;6(7):1077-86. doi: 10.1111/j.1538-7836.2008.02997.x. Epub 2008 Jul 1.

5.

Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.

Argenta C, Ferreira MA, Sander GB, Moreira LB.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S89-92. doi: 10.1016/j.jval.2011.05.017.

6.

Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.

Caprini JA, Tapson VF, Hyers TM, Waldo AL, Wittkowsky AK, Friedman R, Colgan KJ, Shillington AC; NABOR Steering Committee.

J Vasc Surg. 2005 Oct;42(4):726-33.

7.

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.

Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Mayzell G, Spyropoulos AC.

Clin Ther. 2004 Jul;26(7):1149-59.

PMID:
15336480
8.

Safety and low molecular weight heparin in older people in a hospital with ambulatory care.

Chan DK, Ong B, Almafragy H, Karr M, Hung AW, Liu JG.

Arch Gerontol Geriatr. 2006 Sep-Oct;43(2):233-41. Epub 2005 Dec 15.

PMID:
16359739
9.

Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.

Kahler ZP, Beam DM, Kline JA.

Acad Emerg Med. 2015 Jul;22(7):796-802. doi: 10.1111/acem.12713. Epub 2015 Jun 25.

10.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
11.
12.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B, Pollack CV.

J Med Econ. 2016;19(1):84-90. doi: 10.3111/13696998.2015.1096274. Epub 2015 Oct 27.

PMID:
26390315
13.

Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.

LaMori JC, Shoheiber O, Mody SH, Bookhart BK.

Clin Ther. 2015 Jan 1;37(1):62-70. doi: 10.1016/j.clinthera.2014.10.024. Epub 2014 Dec 15. Erratum in: Clin Ther. 2015 Oct 1;37(10):2382-3.

PMID:
25524389
14.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.

Robertson L, Jones LE.

Cochrane Database Syst Rev. 2017 Feb 9;2:CD001100. doi: 10.1002/14651858.CD001100.pub4. Review.

PMID:
28182249
15.

Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.

Santamaría A, Juárez S, Reche A, Gómez-Outes A, Martínez-González J, Fontcuberta J; ESFERA Investigators.

Int J Clin Pract. 2006 May;60(5):518-25.

PMID:
16700847
16.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
17.

Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.

Huse DM, Cummins G, Taylor DC, Russell MW.

Am J Manag Care. 2002 Jan;8(1 Suppl):S10-6.

18.
19.

Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.

Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.

J Med Econ. 2014 Oct;17(10):691-5. doi: 10.3111/13696998.2014.946993. Epub 2014 Aug 4.

PMID:
25065536
20.

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators.

J Thromb Haemost. 2006 Jun;4(6):1246-52.

Supplemental Content

Support Center